このエントリーをはてなブックマークに追加
ID 27694
本文ファイル
著者
Takahashi, Shunsuke
Taniguchi, Yoshihiko
Arakawa, Tetsuji
Kawai, Toru
Ito, Takafumi
Yorioka, Noriaki
キーワード
Macrophage
Mizoribine
Peritoneal dialysis
Peritoneal fibrosis
Experimental peritoneal fibrosis
rat model
NDC
医学
抄録(英)
Background/Aims: Peritoneal fibrosis is a serious complication of peritoneal dialysis (PD). It has been reported that administration of mizoribine, an effective immunosuppressant, ameliorated renal fibrosis in a rat model of unilateral ureteral obstruction. We therefore examined the effects of mizoribine in an experimental model of peritoneal fibrosis. Methods: 24 rats were given a daily intraperitoneal injection of chlorhexidine gluconate and ethanol dissolved in saline. The rats were divided into three groups (n = 8 per group) that received either vehicle or mizoribine at a dose of 2 or 8 mg/kg once a day. 28 days after the start of the treatments the rats were sacrificed and peritoneal tissue samples collected. Macrophage infiltration (ED1), myofibroblast accumulation (alpha-smooth muscle actin (SMA)) and expression of type III collagen, transforming growth factor (TGF)-beta and monocyte chemotactic protein-1 (MCP-1) were examined by immunohistochemistry. Results: Mizoribine significantly suppressed submesothelial zone thickening and reduced macrophage infiltration. Mizoribine also reduced collagen III+ area and decreased the number of alpha-SMA(+), TGF-beta(+) and MCP-1(+) cells. The magnitude of the changes observed was dose-dependent. Conclusion: The administration of mizoribine prevented the progression of peritoneal fibrosis in this rat model. Mizoribine may represent a novel therapy for peritoneal sclerosis in patients undergoing long-term PD.
掲載誌名
Nephron Experimental Nephrology
112巻
2号
開始ページ
E59
終了ページ
E69
出版年月日
2009
出版者
Karger
ISSN
1660-2129
出版者DOI
言語
英語
NII資源タイプ
学術雑誌論文
広大資料タイプ
学術雑誌論文
DCMIタイプ
text
フォーマット
application/pdf
著者版フラグ
author
権利情報
Copyright (c) 2009 S. Karger AG, Basel
関連情報URL
部局名
医歯薬学総合研究科